MedTrace Logo

Clinical Trials to Assess the Efficacy and Safety of HLIM

NCT03827590 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 487

Last updated 2019-02-08

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of HLIM

Conditions

  • Acute Upper Respiratory Tract Infection
  • Acute Bronchitis

Interventions

DRUG

Test

three times a day for five days

DRUG

Active Comparator Control 1

three times a day for five days

DRUG

Active Comparator Control 2

three times a day for five days

DRUG

Placebo

three times a day for five days

Sponsors & Collaborators

  • SamA Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-29
Primary Completion
2019-05-30
Completion
2019-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03827590 on ClinicalTrials.gov